Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease
Open Access
- 17 February 2011
- journal article
- Published by American Society of Hematology in Blood
- Vol. 117 (7) , 2275-2283
- https://doi.org/10.1182/blood-2010-10-307819
Abstract
Investigation of the effects of rituximab (anti-CD20) on B-cell-activating factor of the tumor necrosis factor family (BAFF) and B cells would betterKeywords
This publication has 49 references indexed in Scilit:
- Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantationProceedings of the National Academy of Sciences, 2010
- Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantationJournal of Clinical Investigation, 2010
- Long-term immune deficiency after allogeneic stem cell transplantation: B-cell deficiency is associated with late infectionsHaematologica, 2010
- Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host diseaseBlood, 2009
- High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host DiseaseClinical Cancer Research, 2007
- T cell–dependent survival of CD20+ and CD20− plasma cells in human secondary lymphoid tissueBlood, 2007
- Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF productionAnnals of the Rheumatic Diseases, 2007
- BAFF‐modulated repopulation of B lymphocytes in the blood and salivary glands of RITUXIMAB‐TREATED patients with Sjögren's syndromeArthritis & Rheumatism, 2007
- Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritisArthritis & Rheumatism, 2006
- Expression and occupancy of BAFF‐R on B cells in systemic lupus erythematosusArthritis & Rheumatism, 2005